Among the patients with PLA2R1-associated membranous nephropathy, 12 patients (92%) in the obinutuzumab or ofatumumab group and 9 patients (56%) in the rituximab group achieved immunological remission at month 6 (P = 0.04) (Table 2). The gene discussed is PLA2R1; the disease is membranous glomerulonephritis.